Testing of the measure is done at the discretion of the PMTF.
Physician Quality Reporting Systems (PQRS)
Currently, five dermatology-specific measures are included in PQRS. These include:
Melanoma: Continuity of Care: This measure measures the percentage of patients, regardless of age, with a current diagnosis of melanoma or a history of melanoma whose information was entered at least once within a 12-month period into a recall system that includes: A target date for the next complete physical skin exam, and a process to follow up with patients who either did not make an appointment within the specified time frame or who missed a scheduled appointment.
Melanoma: Coordination of Care: This measure gauges the percentage of patient visits, regardless of patient age, with a new occurrence of melanoma. They must have a treatment plan documented in the chart that was communicated to the physician(s) providing continuing care within one month of diagnosis.
Melanoma: Overutilization of Imaging Studies: This measure measures the percentage of patients with melanoma, without signs or symptoms, for whom no diagnostic imaging studies were ordered.
Biopsy Follow-Up: This measure measures the percentage of patients whose biopsy results have been reviewed and communicated to the primary care/referring physician and patient by the performing physician. To satisfy this measure, the biopsying physician must review the biopsy results with the patient, communicate those results to the primary care/referring physician, track communication in a log, and document the tracking process in the patient’s medical record. This measure applies to all patients who undergo a biopsy, regardless of diagnosis.
Psoriasis: Tuberculosis Prevention for Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier :
In this at-risk patient group, this measure evaluates whether providers are ensuring active tuberculosis prevention either through yearly negative standard tuberculosis screening tests or are reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test.
NQF-endorsed quality measures
Current NQF-endorsed measures are:
- Melanoma: Overutilization of Imaging Studies: Percentage of patients with stage 0 or IA melanoma, without signs or symptoms, for whom no diagnostic imaging studies were ordered.
- Melanoma: Continuity of Care — Recall System: Patients entered into a recall system with the target date for the next complete physical skin exam specified, at least once within the 12-month reporting period.
The PMTF is working to develop more measures to increase the measure inventory for dermatologists in PQRS.